Abstract. We aimed to monitor the timing of amyloid-␤ deposition in relation to changes in brain function using in vivo
INTRODUCTION
Positron emission tomography (PET) imaging has revolutionized the ability to provide a premortem assessment of the regional and sequential pathological changes concomitant with Alzheimer's disease (AD) [1] . The combination of disease-specific amyloid positron emission tomography (PET) tracers with the neurodegenerative PET biomarker [ 18 F]-fludeoxyglucose (FDG) allows non-invasive monitoring of the extent of AD pathology and its consequent effect on brain function [2, 3] . The presence or absence of these biomarkers assists diagnosis and disease staging [4] , and they are increasingly being used as inclusion criteria and secondary end points in clinical trials [5] .
Transgenic mouse models that overexpress APP and PS1 mutations produce high levels of amyloid-␤ and are used to investigate AD pathology in a reductionist manner [6] . With the availability of small animal PET scanners, PET imaging represents an ideal cross-species tool that enables measurement of the same molecular processes in humans and animal models. Application of amyloid tracers and [ 18 F]-FDG imaging in mouse models could then aid in basic understanding of amyloid-related neurodegeneration and additionally serve as readouts of therapeutic efficacy of novel therapeutics. With this prospect of improving translation from basic to clinical research, PET imaging has become a thriving field in AD. Notwithstanding some initial negative findings [7] [8] [9] , amyloid imaging has been successfully back-translated in a number of mouse models [10] [11] [12] [13] . Similar to the clinical situation, research has now moved from validating to improving this technology. We, and others, have previously described discrepancies between in vivo uptake of amyloid tracers and gold standard ex vivo autoradiography [10, 11] and histology [14] [15] [16] hypothesized to derive from two main factors. The first relates to partial volume and spill over effects (PVE) . While PET systems have superior resolution to their clinical counterparts, it is insufficient in relation to the small size of mouse brain structures resulting in difficulties with accurate radioactivity measurements [17] . A second and related issue is that of high non-specific white matter uptake of amyloid tracers [18] , especially in the case of [ 18 F]-florbetaben and [ 18 F]-AV45 whose metabolism is known to result in brain penetrant radiometabolites [19, 20] . Methods to counteract these effects are required so that preclinical amyloid imaging can sensitively monitor changes in amyloid burden in relation to disease progression and therapeutic response.
While small animal amyloid imaging has made considerable progression, the utility of [ 18 F]-FDG as a preclinical biomarker is disputed. Although the clinical phenotype of decreased [ 18 F]-FDG uptake has been reported in mouse models of AD [15, 16, 21, 22] , an equal proportion of studies have reported increased [ 18 F]-FDG uptake [23] [24] [25] [26] . Association studies of amyloid and hypometabolism in patients are complicated by the heterogenity of [ 18 F]-FDG uptake, which is influenced by factors such as age, genetics, comorbidities, and education levels. In this context, animal models have a clear advantage in terms of standardization of genetic and environmental backgrounds. Moreover, a number of therapies that reduced amyloid failed to demonstrate a benefit on cognition [27, 28] . Thus while amyloid imaging can provide a measure of target engagement for anti-amyloid treatments, [ F]-AV45 we conjointly probed a number of issues related to sensitivity. These included a metabolite study to quantify the contribution of radiometabolites to brain imaging and additionally an assessment of the ability of corrections for PVE (PVEC) and reference region normalization to improve early detection of amyloid pathology.
MATERIALS AND METHODS

Animals
TASTPM mice and their WT controls (C57BL/6J) were received in kind from GlaxoSmithKline (Stevenage, UK) through the PharmaCog consortium. TASTPM mice express human mutant amyloid precursor protein (hAPP695swe) and presenilin-1 (M146V) under the control of the neuron specific Thy-1 promoter on a C57BL/6J background and develop insoluble amyloid-␤ deposition as of 4 months of age [29] . A total of 44 male mice (22 WT and 22 TASTPM) were included in the imaging experiment. Male mice were chosen due to their lower mortality rate than females. During the course of the imaging study, 5 transgenic mice died prematurely. Additionally, at every time point an n = 3 for each genotype were sacrificed for histology (animals chosen at random). Table 1 displays the number of animals scanned at each time point and the average weight per genotype.
The metabolite study was performed using 3-month-old male C57BL/6J mice (n = 11, Harlan Laboratories, The Netherlands) and a separate aged cohort of 15-month-old WT and TASTPM mice (both n = 11). All animal work was performed in accordance with the European Ethics Committee (decree 86/609/CEE). The study protocol was approved by the local Animal Experimental Ethical Committee of the University of Antwerp, Belgium (2012-25).
Tracer radiosynthesis
[ 18 F]-AV45 was synthesized from the tosyloxy precursor AV-105 by modification of the method described by Yao and coworkers [30] on a . The metabolite analysis was performed on a young (3-month-old) WT cohort and an aged (15-month-old) cohort of WT and TASTPM mice (n = 11 for each). At 5, 10, 30, and 60 min post injection (p.i.), blood was withdrawn via cardiac puncture and the brain was rapidly removed by dissection. Plasma samples (200-400 l), obtained after centrifugation of blood at 4500 × g for 7 min, were mixed with equal amounts of ice-cold acetonitrile for deproteination. The brain was homogenized in ice-cold acetonitrile (1 ml) and both samples were subsequently centrifuged at 4000 × g for 4 min to precipitate denatured proteins. Supernatant was separated from the precipitate and both fractions were counted in a gamma counter to calculate the extraction efficiency (percent recovery of radioactivity in the acetonitrile). 100 l of supernatant was loaded onto a pre-conditioned reverse-phase (RP)-HPLC system (Waters XBridge, 150×4.6 mm, 5 m HPLC column + Phenomenex security guard precolumn) and eluted with acetonitrile: NaOAc 0.05M pH5.5 (50:50 v/v) buffer at a flow rate of 1 ml/min. RP-HPLC fractions were collected at 0.5 min intervals for 13 min and radioactivity measured in a gamma counter. The radioactivity due to [ 18 F]-AV45 and each radiometabolite was expressed as a percentage of the total peak areas based on radiochromatograms. All samples had an authentic internal cold standard of AV-45 (1 mg/ml) for UV crossvalidation. [31] prior to scanning and plasma glucose levels were monitored in duplicate by a blood glucose meter (One Touch Ultra 2, Life Scan, France) immediately after tracer injection.
PET data acquisition and processing
20 min static PET acquisitions were acquired on two Siemens Inveon PET-CT scanners (Siemens Preclinical Solution, Knoxville, TN) [32] anesthesia was induced by inhalation of isoflurane (5% for induction, and 2% for maintenance during preparation and scanning) supplemented with oxygen. The core body temperature of the animals was maintained via a temperature controlled heating pad. In the case of [ 18 F]-FDG scans, animals in which a blood glucose measure could not be obtained were excluded due to the requirement of a glucose value for normalization purposes (one WT mouse at 9 months and one TG at 6 months). All scans were carefully assessed for movement, in this case, animals were rescanned.
All PET data was reconstructed with twodimensional ordered subset expectation maximization (OSEM2D) [33] algorithm using 4 subsets and 16 iterations following Fourier rebinning (FORE) [34] . The energy and timing window was set to 350-650 keV and 3.432 ns, respectively. The PET images were reconstructed on a 128 × 128 × 159 grid with a pixel size of 0.776 × 0.776 × 0.776 mm. Normalization, dead time, randoms, CT-based attenuation and single scatter simulation (SSS) [35] corrections were applied. A CT was acquired subsequent to all PET scans. CT imaging was done using a 220 degrees rotation with 120 rotation steps. Voltage and amperage are set to 80 keV and 500 A, respectively. The CT images were reconstructed using the Feldkamp filtered-backprojection algorithm.
Image processing was performed in PMOD v3.3 (PMOD technologies, Switzerland). Individual PET images were spatially normalized into the space of a predefined mouse brain template [36] by matching the individual animal specific CT to the CT template through rigid and elastic transformations and applying the same transform to the PET which is by default matched to its CT via the PET/CT scanner hardware. Processed images were subsequently co-registered with a predefined mouse brain volume-of-interest (VOI) template aligned with the aforementioned Mirrione CT/MRI atlas and tracer uptake values were extracted for each delineated VOI.
VOI-based partial volume effect correction was performed using the built-in function in PMOD [37] with the Mirrione mouse brain template. PVEC was performed using a spatial resolution of 1.5 mm × 1.5 mm × 1.5 mm isotropically and spatially invariant in PET space. Therefore, the VOI template is transformed back using the non-rigid inverse transform of the previous matching for the individual 
Immunohistochemistry
Animals were sacrificed and brain tissue was fixed, paraffin-embedded and cut into 5 m coronal sections. Sections were de-waxed with xylene and rehydrated by submerging in a graded series of ethanol with decreasing concentrations. First sections were bleached with potassium permanganate (3 min), rinsed in water (1 min), decolorized in oxalic acid (1 min) and rinsed again (1 min). Thereafter antigen retrieval was performed at room temperature by immersion in formic acid (10 min). Endogenous peroxidase activity was quenched by rinsing in peroxidase blocking solution (DAKO S2023) (5 min). Sections were then incubated with 4G8 primary antibody (Eurogentec SIG-39200, 1/20, 000) for 30 min (2 cycles of 15 min with rinse between incubations). Following this, sections were thoroughly rinsed in wash buffer and subsequently incubated in peroxidase coupled secondary antibody (30 min) (Envision Mouse). Sections were washed in buffer and immunodetection was performed by treatment with the chromogenic 3-3 diaminobenzidine (DAB) solution. Finally sections were counterstained with hematoxylin, dehydrated by submerging in a series of ethanol, fixed in xylene, mounted, and coverslipped. For sections stained for amyloid-␤, virtual images were acquired using a Mirax Digital Slide Scanner (Carl Zeiss) and image analysis was performed using the Definiens analysis software package v1.5.
Statistics
Statistical analysis was conducted in JMP pro Version 12 (SAS Institute Inc., USA) and GraphPad Prism v6 (GraphPad Software, USA). To assess quantification methods of [ 18 F]-AV45 we compared the mean difference between WT and TASTPM uptake and then calculated the percentage difference between methods as (New data -original data)/(New data + original data)/2 * 100. The "original data" refers to [ 18 F]-AV45 quantified as %ID/g and "new data" refers to PVE corrected or PVE corrected and cerebellar normalized data. For the longitudinal study, we fitted a linear mixed model to investigate the relationship between tracer uptake ([ 18 F]-FDG or [ 18 F]-AV45), age and genotype. This method was chosen as it accounts for missing data, unbalanced designs and repeated observations within the same individual. Age and genotype were entered as "fixed effects" and mouse ID was incorporated as a random intercept ("random effect") to model subject specific responses. We additionally tested for age*genotype interactions within this model. Pairwise differences in tracer uptake between genotypes at each time point were investigated using multiple unpaired t-tests (with Sidak-Bonferroni correction). The correlation of PET data to ex vivo histology was expressed using Pearson's correlation coefficient. Assumptions for the use of parametric t-tests and Pearson's correlation were met. Significance levels are given to four decimal points.
RESULTS
[ 18 F]-AV45 undergoes rapid peripheral metabolism with production of several brain penetrant metabolites
Four main radiometabolite peaks were detected in both the brain and plasma eluting with retention times (Rt) of 1.6 min (M1), 1.85 min (M2), 3 min (M3), and 3.8 min (M4). An additional radiometabolite was observed in the brain eluting at 6.4 min (M5) very close to the intact tracer. Representative radiochromatograms for plasma and brain at 30 min p.i. are shown in Supplementary Figure 2 . Figure 1A depicts the detection of [ 18 F]-AV45 and radiometabolites in plasma of healthy young WT mice. Intact [ 18 F]-AV45 accounted for 27.1 ± 7.3% of total radioactivity at 5 min p.i. decreasing rapidly to 7.9 ± 0.73% at 10 min p.i., 4.5 ± 1.8% (n = 2) and 5.21% (n = 1) at 30 and 60 min p.i., respectively. The most polar radiometabolite M1 accounted for the majority of plasma radioactivity at all time points increasing from 33.4 ± 11.3% at 5 min p.i. to 60.4 ± 7.4% at 60 min p.i. Figure 1B illustrates the uptake of [ 18 F]-AV45 and radiometabolites in the brain of young WT mice. At 5 min p.i. levels of intact tracer in the brain were comparable to that detected in the plasma (28.6 ± 1.9% and 27.1 ± 7.3%, respectively). At all later time points, intact tracer levels were higher in the brain representing 24.6 ± 7.6%, 10.6 ± 4.3%, and 11.0 ± 1.4% of total radioactivity at 10, 30, and 60 min p.i., respectively. M3 was the dominant metabolite in the brain with highest levels at 10 and 30 min pi (35.6 ± 3.6% and 37.7 ± 3.2%) then declining to 26.6 ± 1.7% at 60 min p.i. The most polar metabolite M1 accumulated appreciably over time representing 23.61 ± 2.2% of total brain radioactiv- ity by 60 min p.i. (Fig. 1B) . While the extraction yields from plasma remained relatively constant (85.8 ± 3.9% at 5 min p.i. to 87.2 ± 0.7% at 60 min p.i.), the extraction of radioactivity from the brain decreased as a function of time (86.1 ± 1.2% at 5 min p.i. to 65.1 ± 4.8% at 30 min p.i.). Results obtained from the aged WT and TASTPM cohorts were largely congruent with those described for young WT (Supplemental Table 2 ).
TASTPM mice demonstrate age-dependent increases in [ 18 F]-AV45 uptake
The uptake of [ 18 F]-AV45 averaged over the WT and TASTPM groups is visualized across time points in Fig. 2 . Figure 3A- F]-AV45 uptake in TASTPM mice. TASTPM uptake was significantly higher at 9 months in the cortex (t (26) = 4.94, p < 0.0001), thalamus (t (26) = 7.93, p < 0.0001), and hippocampus (t (26) = 4.96, p < 0.0001), in the striatum at 12 months (t (19) = 6.82, p < 0.0001) and remains significantly higher at all further time points. In the TASTPM mice (n = 5) that underwent scanning at all time points, the average % increase from baseline was 23.7 ± 8.4% in the cortex, 28.5 ± 8.6% in the thalamus, 35.6 ± 8.8% in the hippocampus, and 19.2 ± 9.4% in the striatum. Figure 6E shows representative images from immunostained brain slices of TASTPM mice at each age. Plaque pathology was absent in the cerebellum of TASTPM mice (Supplementary Figure 3) and in the brains of WT mice.
Reductions in [ 18 F]-FDG uptake do not worsen with age in TASTPM mice
DISCUSSION
Translation of basic research findings into clinical drug development depends largely on animal models as a means to uncover pathomechanisms and to predict therapeutic efficacy. A lack of appropriate biomarkers that transfer from animal models to human is widely acknowledged as a rate-limiting step in translational research [39] . PET imaging is particularly attractive for animal model-based research and represents a translational tool that would allow for greater conformity between human and animal studies. We herein investigated the potential of [ 18 F]-AV45 and [ 18 F]-FDG as translational biomarkers in double transgenic TASTPM mice.
[ 18 F]-AV45 is gaining wide application in clinical and preclinical research as a non-invasive marker of disease progression. Excellent brain penetrance, rapid washout kinetics and a high affinity against amyloid-␤ are among the qualities that recommend [ 18 F]-AV45 as a suitable imaging agent [20, 40] . Being fluorinated, it has the added benefits of increased availability in comparison to its predecessor, [ 11 C]-PiB. However, one disadvantage of [ 18 F]-AV45 is its notably lower dynamic range due to high non-specific white matter binding [41] , which we have previously shown to result in smaller differences between WT and transgenic mice [16] . Herein, as part of our investigations into the sensitivity of [ 18 F]-AV45, we aimed to assess the production and brain uptake of radiometabolites. While fast metabolism and brain penetrant radiometabolites of [ 18 F]-AV45 have been reported [20] , we believe that both the extent of plasma clearance and contribution of radiometabolites to brain imaging has been underestimated. In contrast to a previous report of a plasma half-life of <30 min [20] , we herein found a halflife of <5 min. The contribution of radiometabolites to brain imaging is substantial with radiometabolites comprising 70% of brain radioactivity already at 5-10 min. Moreover, these radiometabolites bind and are retained in the brain as shown by the decreasing extraction efficiency from brain tissue (from 86.1% at 5 min p.i. to 65.1% at 30 min p.i. [42, 43] and thus such a mechanism could account for the absence of agerelated decreases in [ 18 F]-FDG uptake. However, in our previous study of TASTPM mice at 13.5 months, we detected significant reductions in [ 18 F]-FDG uptake despite immunohistochemistry demonstrating an increased number of microglia and astrocytes [15] . In this former study, we found the thalamus to demonstrate the most pronounced reductions in [ 18 F]-FDG and herein the thalamus also demonstrated the greatest reductions in [ 18 F]-FDG uptake, albeit at 9 M. The reduced statistical power at 12 and 15 months due to the lower sample size may have limited the ability to determine changes in [ 18 F]-FDG uptake at these ages and could account for differences to our findings in 13.5 month TASTPM mice.
Amyloidosis models do not recapitulate the entire disease spectrum of AD and are devoid of tau tangle pathology and overt neuronal loss [44] . Authors' disclosures available online (http://jalz.com/manuscript-disclosures/16-0760r1).
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